Novo Nordisk loses US patent, paves way for Caraco's generic Prandin
This article was originally published in Scrip
Executive Summary
A federal judge has found that a Novo Nordisk US patent, covering the combination use of repaglinide and metformin for treatment of type 2 diabetes, is invalid because of obviousness and unenforceable due to inequitable conduct at the US Patent and Trademark Office, potentially opening the way for Caraco Pharmaceutical to market a generic Prandin.